Ignyta revises terms of entrectinib license agreement with Nerviano
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 8:40AM CST
RXDX: 6.70 (+0.01)
Ignyta Announces Amendment to License Agreement with Nerviano
Business Wire - Mon Dec 15, 6:00AM CST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that it has entered into an amendment to its license agreement with Nerviano Medical Sciences, S.r.l. relating to its entrectinib (formerly RXDX-101) product candidate. The amendment modifies the milestones that would trigger the initial three milestone payments specified in the license agreement. Pursuant to the amendment, the initial milestone payment of $10 million will be due and payable to Nerviano by December 31, 2014, and the second and third milestone payments will be triggered by revised clinical and/or regulatory events relating to entrectinib or other licensed products. The amounts of such milestone payments have not changed.
RXDX: 6.70 (+0.01)
Ignyta Receives Approval of Nonproprietary Name Entrectinib for Lead Product Candidate, RXDX-101
Business Wire - Tue Dec 09, 6:00AM CST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that the World Health Organization (WHO) has approved the international nonproprietary name (INN) "entrectinib" for the company's lead product candidate, RXDX-101. INNs facilitate the identification of active pharmaceutical ingredients, and each INN is a globally recognized unique name.
RXDX: 6.70 (+0.01)
Ignyta Announces CLIA Certification Achieved by its Diagnostic Laboratory
Business Wire - Tue Dec 02, 6:00AM CST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that its San Diego diagnostic laboratory successfully passed the State of California survey for CLIA (Clinical Laboratory Improvement Amendments) certification. The State of California inspector granted Ignyta permission to begin offering molecular diagnostic services to patients, including those in the company's clinical trials.
RXDX: 6.70 (+0.01)
Ignyta to Present at Upcoming Investor Conferences
Business Wire - Tue Nov 25, 6:00AM CST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, announced today that its management will be making company presentations at the following investor conferences in December 2014:
RXDX: 6.70 (+0.01)
Ignyta Announces RXDX-101 Presentations at the 2014 EORTC-NCI-AACR 'Molecular Targets and Cancer Therapeutics' Conference
Business Wire - Tue Nov 18, 3:00PM CST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced the acceptance of two abstracts for poster presentations relating to RXDX-101, the company's proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. The poster presentations will be held on November 20-21, 2014 in Barcelona, Spain.
RXDX: 6.70 (+0.01)
Ignyta's (RXDX) CEO Jonathan Lim on Q3 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 07, 6:06PM CST
RXDX: 6.70 (+0.01)
Ignyta posts 3Q loss
Automated Insights - Fri Nov 07, 3:07PM CST
SAN DIEGO (AP) _ Ignyta Inc. (RXDX) on Friday reported a loss of $10.7 million, or 55 cents per share, in its third quarter.
RXDX: 6.70 (+0.01)
Ignyta misses by $0.12
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 3:03PM CST
RXDX: 6.70 (+0.01)
Ignyta Announces Third Quarter 2014 Company Highlights and Financial Results
Business Wire - Fri Nov 07, 3:00PM CST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced company highlights and financial results for the third quarter ended September 30, 2014.
RXDX: 6.70 (+0.01)
Ignyta to Chair the Institute of Medicine's National Cancer Policy Forum Workshop on Molecularly Targeted Cancer Therapies
Business Wire - Mon Nov 03, 3:00PM CST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that its Chief Medical Officer, Adrian Senderowicz, M.D., has been selected to serve as Workshop Planning Committee Chair for the workshop entitled Policy Issues in the Development and Adoption of Molecularly Targeted Therapies for Cancer. The event will be hosted by the Institute of Medicine's National Cancer Policy Forum on November 10 and 11, 2014 at the Keck Center of the National Academies in Washington, D.C.
RXDX: 6.70 (+0.01)
Ignyta to Report 2014 Third Quarter Company Highlights and Financial Results and Host Conference Call on November 7, 2014
Business Wire - Fri Oct 31, 4:29PM CDT
Ignyta, Inc. (Nasdaq: RXDX), an precision oncology biotechnology company, announced today that it will release its third quarter 2014 financial results after the market closes on Friday, November 7, 2014. Ignyta management will host a conference call that same afternoon at 4:30 p.m. ET (1:30 p.m. PT) to provide company highlights, review the financial results and answer questions.
RXDX: 6.70 (+0.01)
Ignyta to Host Investor Meeting with Oncology Key Opinion Leaders on October 14, 2014
Business Wire - Thu Oct 02, 3:00PM CDT
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, announced today that it will host a Key Opinion Leader Breakfast on Tuesday, October 14, 2014 from 8:00-9:30 a.m. Eastern time in New York City.
RXDX: 6.70 (+0.01)
Ignyta Secures $31 Million Term Loan Facility from Silicon Valley Bank
Business Wire - Wed Oct 01, 3:30PM CDT
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, announced today that it has secured a $31 million term loan facility from Silicon Valley Bank. Under the loan facility, the company received initial funding of $21 million, approximately $11 million of which was used to repay the company's existing loan with Silicon Valley Bank, and has a conditional option to receive an additional $10 million.
RXDX: 6.70 (+0.01)
Ignyta Announces Interim Data from RXDX-101 Phase I Clinical Trial at 2014 ESMO Congress
Business Wire - Sun Sep 28, 7:00AM CDT
--To date, one complete response in a patient with a ROS1 alteration, partial responses in five patients with each of TrkA, ROS1 and ALK alterations, and prolonged stable disease in two patients
RXDX: 6.70 (+0.01)
Ignyta to Present at Livingston Securities Life Science Stakeholders Summit
Business Wire - Thu Sep 25, 3:00PM CDT
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, announced today that Jacob Chacko, M.D., Chief Financial Officer, will make a presentation at the Livingston Securities Life Science Stakeholders Summit on October 1, 2014 at 1:30 p.m. Eastern time (10:30 a.m. Pacific time) in Philadelphia, PA.
RXDX: 6.70 (+0.01)
Nasdaq stocks posting largest percentage decreases
AP - Fri Sep 19, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
EVOK: 5.50 (-0.26), ALCS: 0.30 (+0.01), UNXL: 5.77 (+0.07), RXDX: 6.70 (+0.01), FULL: 4.76 (-0.01), RLYP: 30.35 (-0.22), BBSI: 28.34 (+0.38), NVSL: 8.58 (+0.09), RPRX: 8.88 (+0.24), HGSH: 4.60 (-0.06), LPCN: 5.15 (+0.01), NYNY: 7.89 (+0.32)
Ignyta to Participate in Precision Medicine Panel Discussions with Other Thought Leaders
Business Wire - Wed Sep 17, 6:00AM CDT
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, today announced that its Chairman and CEO, Jonathan Lim, M.D., has been invited to participate in upcoming panel discussions relating to innovation in Rx/Dx strategies and novel science developments in precision medicine.
BIIB: 340.89 (+5.13), RXDX: 6.70 (+0.01)
Ignyta Announces RXDX-101 Phase I Data Presentation at the 2014 ESMO Congress
Business Wire - Mon Sep 15, 3:00PM CDT
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, today announced that interim results from the first-in-human ALKA-372-001 Phase I clinical trial of RXDX-101, the company's proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, was selected for presentation in a poster discussion session at the 2014 Congress of the European Society for Medical Oncology (ESMO), which is being held from September 26-30, 2014 in Madrid, Spain.
RXDX: 6.70 (+0.01)
Ignyta (RXDX) Jumps: Stock Adds 5.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 7:51AM CDT
Ignyta, Inc. (RXDX) was a big mover last session, as its shares rose nearly 6% on the day.
LCI: 42.29 (+1.79), ENDP: 72.10 (+0.34), RXDX: 6.70 (+0.01), HPTX: 21.91 (-0.08)